






Drug supply rising globally

- **Cocaine** supply reached a record high in 2022, with more than 2,700 tons of cocaine manufactured; 20 per cent more than a year earlier and three times the amount manufactured in 2013.
- The market for **ketamine** is rapidly expanding into new geographical areas.
- In the Near and Middle East, "captagon" and methamphetamine markets seem to be converging, with a sharp increase in seizures reported and an expansion outside traditional markets.
- Global seizures of amphetamine-type stimulants (ATS) remain at historically high levels as a number of "emerging markets" continue growing.
- Countries in **Africa** are increasingly affected by drug trafficking and the use of new and dangerous **drug "cocktails"**.






SELECTED DRUG MIXTURES AND CONCOCTIONS REPORTED IN AFRICA







Most commonly used synthetic drugs, by drug type, 2022 or latest year for which data was reported



Source: UNODC, responses to the annual report questionnaire.

Note: The most common synthetic drug ranked for a country is based on the group, class of a drug or a specific drug that was reported by a country. The category amphetamines includes methamphetamine and amphetamine, and the term was used where a country did not specify or reported equal ranking for methamphetamine and amphetamine and amphetamine and the term was used where a country did not specify or reported equal ranking for methamphetamine and amphetamine and amphetamine.

July 26, 2024





Most commonly <u>used stimulant drug</u>, in terms of number of past-year users, 2022 or latest year for which data are available

Legend

Most commonly used stimulant by country (2022 or latest year available)

- Methamphetamine
- Amphetamine
- Other amphetamine-type stimulants (khat)
- "Ecstasy"-type substances


Cocaine

Synthetic cathinones

Synthetic cathinones and other stimulant NPS (recorded as designer stimulants)

Non-medical use of pharmaceutical products containing amphetamine-type stimulants


No data







Most commonly <u>ATS seized</u> by country, based on kg equivalents seized during 2018-2022








TREND IN INDIVIDUAL SEIZURES OF OPIATES AND OF <u>NPS AND ATS</u> IN <u>CENTRAL ASIA, TRANSCAUCASIA AND</u> <u>EASTERN EUROPE</u>, 2012–2023

DISTRIBUTION OF NPS AND ATS REPORTED IN INDIVIDUAL DRUG SEIZURES IN EASTERN EUROPE, CENTRAL ASIA AND TRANSCAUCASIA, 2020–2023









Global distribution of drug seizure cases, 2021-2022

Long-term trends in quantities of drugs seized, 1998–2022






Source: UNODC, responses to the annual report questionnaire






Quantities of methamphetamine seized, by region and subregion, and reported qualitative trends in methamphetamine trafficking, 1998–2022



Trends in the use and treatment of amphetamine-type stimulants (ATS), 2012–2022



Source: UNODC, responses to the annual report questionnaire


Note: The index of trends in the use of ATS is based on qualitative information on trends in the use of amphetamine-type stimulants reported by Member States (on average, 44 countries per year for ATS-related treatment trends and 46 for ATS use over the period 2012–2022). The trend line is calculated on the basis of the number of countries reporting increases minus the number of countries reporting decreases (2 points for "large increase", 1 point for "some increase", 0 points for "stable", -1 point for "some decrease", -2 points for "large decrease"). In 2020, the data collection instrument was updated and contained "ecstasy"-type substances as a separate drug class, not including them in the category of amphetamine-type stimulants, which continues to include amphetamines and certain cathinones under international control (mephedrone, methylone, methychnen and cathinone).





Trend in the quantities of methamphetamine seized in significant seizure events in South-West Asia,

Significant individual seizures of methamphetamine in South-West Asia and neighbouring subregions, excluding Afghanistan, 2020–2023



Source: UNODC, Drugs Monitoring Platform.


Source: UNODC, Drugs Monitoring Platform.

Drug use continues to increase and harm people, particularly young people


- Almost 292 million people have used a drug in the past year (5.6% of population aged 15-64), 20% more than
 a decade before (5.2%; prevalence rate now 8% higher)
- An estimated 64 million people were suffering from <u>drug use disorders</u> in 2022 (1.2 per cent of population aged 15-64), slightly up from 59 million in 2015.
- Most <u>drug use disorders</u> and drug treatment are related to the harmful patterns of use of cannabis and opioids while most <u>drug related deaths</u> are related to opioids, followed by [sedatives] cocaine and ATS.
- An estimated 13.9 million people injected drugs (0.3%) in 2022 of which 6.8 million live with hepatitis C and 1.6 million with <u>HIV</u> and 1.4 million with HIV and hepatitis C. The ris those who inject drugs than for those who do not inject drugs.
 TOXICOLOGICAL FINDINGS IN REPORTED CASES OF OVERDOSES IN 66 COUNTRIES.
- Revival of stimulant drug use such as cocaine and "ecstasy", following pandemic;
- Drugs are still used more by men (76%) than women (24%); synthet gender gap.
- New means of drug delivery are negatively impacting young people; affected by drug use.




2022 OR LATEST YEAR AVAILABLE




People under 25 years old in treatment, 2022







Users of selected drug groups by sex



Source: UNODC, responses to the annual report questionnaire






amphetamine-type stimulantss

opioids

other drugs

≤

Most common drug in drug treatment, 2022 (or latest year for which data was reported)




Source: UNODC, responses to the annual report questionnaire

July 26, 2024

Significant treatment gap


- Only about 1 in 11 people with drug use disorders received drug treatment in 2022 globally, a decrease from 2015.
- Drug-related treatment coverage is lower amongst women than it is amongst men in all five global regions. About 1 in 18 women with drug use disorders received treatment globally in 2022, while the ratio was 1 in 7 for men.



Access to controlled medicines remains limited

- The availability of opioids for medical consumption remains limited in the global South;
- Some 87 per cent of the world's population do not have adequate access to pharmaceutical opioids for pain relief and care.

AMOUNT OF OPIOIDS UNDER INTERNATIONAL CONTROL (EXCLUDING PREPARATIONS) AVAILABLE FOR MEDICAL CONSUMPTION, BY COUNTRY INCOME LEVEL GROUP, 2018 AND 2022



Sources: UNODC calculations based on the World Bank classification of countries by income levels; INCB, Narcotic Drugs 2023: Estimated World Requirements for 2024 – Statistics for 2022 (E/INCB/2023/2); and INCB, Psychotropic Substances 2023: Statistics for 2022 – Assessments of Annual Medical and Scientific Requirements for 2024 (E/INCB/2023/3).





Trends in the availability of opioids under international control (excluding preparations) for medical consumption, by region and subregion, 2015–2022

High-availability subregions

Low-availability subregions



Source: UNODC calculations based on the following INCB reports: Narcotic Drugs: Estimated World Requirements for 2023 – Statistics for 2021 (E/INCB/2022/2), and previous years; and Psychotropic Substances: Statistics for 2021 – Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substance of 1971 (E/INCB/2022/3), and previous years.






<u>1961 Single Convention:</u> <u>Preamble:</u>

... Recognizing that the medical use of <u>narcotic</u> <u>drugs</u> continues to be <u>indispensable for the</u> <u>relief of pain and</u> <u>suffering</u> and that adequate provision must be made to <u>ensure the availability</u> of narcotic drugs for such purposes...

Art. 9: The Board, in cooperation with Governments... shall endeavour to limit the cultivation, production, manufacture and use of drugs to an adequate amount required for medical and scientific purposes, to ensure their availability for such [medical and scientific] purposes...

Level of availability for consumption of pharmaceutical opioids in defined daily doses for statistical purposes per million inhabitants per day, 2020-2022 (or latest year available)



Source: UNODC calculations based on the following INCB reports: Narcotic Drugs: Estimated World Requirements for 2023 – Statistics for 2021 (E/INCB/2022/2), and previous years; ana Psychotropic Substances: Statistics for 2021 – Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substance of 1971 (E/INCB/2022/3), and previous years.





Drastic contraction of the Afghan opiate market






FIG. 3 Opium cultivation and production in Afghanistan, 1994–2023


Source: UNODC, Afghanistan Opium Survey 2023, August 2023.

Main identified source countries of opiates in consumer markets, 2018-2022





TREND IN THE QUANTITIES OF HEROIN AND METHAMPHETAMINE SEIZED IN SIGNIFICANT SEIZURE EVENTS, POTENTIALLY LINKED TO PRODUCTION IN AFGHANISTAN, 2020–2023



Methampthetamine seized in South-West Asia, Central Asia and Oman


2023






Potential consequences of the contraction of the Afghan opiate market

Legal consumption of methadone and buprenorphine (mostly used in opioid substitution treatment), 2020-2022



Source: INCB, Narcotic Drugs; Estimated World Requirements for 2024; Statistics for 2022 (E/INCB/2023/2).

Note: S-DDDs refers to "defined daily doses for statistical purposes" as defined by INCB. They are technical units of measurements for the purpose of statistical analysis and are not recommended daily prescription doses; actual doses may differ depending on treatments required and medical practices.



Sources: UNODC calculations based on the World Bank classification of countries by income levels; INCB, Narcotic Drugs 2023: Estimated World Requirements for 2024 – Statistics for 2022 (E/INCB/2023/2); and INCB, Psychotropic Substances 2023: Statistics for 2022 – Assessments of Annual Medical and Scientific Requirements for 2024 (E/INCB/2023/3).


METHADONE AND BUPRENORPHINE AVAILABLE FOR MEDICAL CONSUMPTION (EXCLUDING PREPARATIONS), 1998–2022





Potential consequences of the contraction of the Afghan opiate market


Number of opioid users and proportion of opiate users thereof, 2022 (or most recent year)








Drug supply via the darkweb



Source: Hikari labs data.

Note: Data refer to minimum stacked market sales of different products and services, of which drugs accounted for some 90 per cent, and are presented as seven-day averages. All data shown reflect minimum sales as the current web-cravier techniques do not cover all sites on a specific market and because not all customers leave feedback, information which is used to arrive at total sales figures. Recent data shown are grassly under-represented (due to low coverage ratios), notably for Hydra market, the world's largest darknet market prior to its dismantling in April 2022.





Source: Chainanalysis, The 2022 Crypto Crime Report.





Drug supply via the darkweb










Drug supply via the darkweb

Main darknet markets and fraud shops identified via the blockchain analysis, 2022


Main darknet markets and fraud shops identified via the blockchain analysis, 2023







Crypto inflows from Western-domiciled exchanges to darknet markets, analyzed via blockchains, 2023



July 26, 2024



